Compare INLF & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLF | BGLC |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | China | Malaysia |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 10.1M |
| IPO Year | 2025 | N/A |
| Metric | INLF | BGLC |
|---|---|---|
| Price | $0.43 | $3.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 77.7K | 8.0K |
| Earning Date | 09-29-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,332,282.00 | $9,465,006.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.11 | 2.21 |
| 52 Week Low | $0.42 | $2.01 |
| 52 Week High | $21.00 | $15.60 |
| Indicator | INLF | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 27.04 | 24.73 |
| Support Level | $0.43 | $3.02 |
| Resistance Level | $0.45 | $3.52 |
| Average True Range (ATR) | 0.03 | 0.21 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 0.96 | 2.81 |
INLIF Ltd, through its subsidiary, is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. In addition, it offers installation and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. The company portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.